SCHEMBL85484

SCHEMBL85484

COc1cc(C)c(C(C)(C)C)cc1C(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
CYP3A4 P08684 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
ADRA2A P08913 1/20 0.47
ADRA2C P18825 1/20 0.47
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
HTR2A P28223 1/20 0.47
CA2 P00918 2/20 0.39
CA1 P00915 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
RARA P10276 2/20 0.35
RARB P10826 2/20 0.35
RARG P13631 2/20 0.35
ACHE P22303 2/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19337383 0.91 LMNA (0.61) LMNATP53CYP3A4HPGDALOX15
SCHEMBL12224029 0.88 LMNA (0.57) LMNATP53CYP3A4HPGDALOX15
SCHEMBL18574229 0.88 CYP3A4 (0.52) LMNATP53CYP3A4HPGDALOX15
SCHEMBL31589074 0.86 LMNA (0.45) LMNATP53CYP3A4HPGDALOX15
SCHEMBL11436543 0.86 LMNA (0.45) LMNATP53CYP3A4HPGDALOX15
SCHEMBL12388583 0.86 LMNA (0.61) LMNATP53CYP3A4HPGDALOX15
SCHEMBL92809 0.85 CYP3A4 (0.64) LMNATP53CYP3A4HPGDALOX15
SCHEMBL28892877 0.84 ALOX15 (0.38) LMNATP53CYP3A4HPGDALOX15
SCHEMBL13939800 0.83 ALOX15 (0.68) LMNATP53CYP3A4HPGDALOX15
SCHEMBL398164 0.83 CYP3A4 (0.74) LMNATP53CYP3A4HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051762-A1 POLYCATIONIC COMPOUNDS AND USES THEREOF POLYMEDIX, INC. 2014-02-20 US disclosed
US-8129566-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2012-03-06 US disclosed
US-20110124664-A1 Polycationic Compounds And Uses Thereof POLYMEDIX, INC. (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124664-A1 Polycationic Compounds And Uses Thereof VEGFA, VHL, PGF LMNA 3716/4885TP53 30/4885CYP3A4 4721/4885
US-20140051762-A1 POLYCATIONIC COMPOUNDS AND USES THEREOF VEGFA, VHL, PGF LMNA 3716/4885TP53 30/4885CYP3A4 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.